1. Genetics and Genomics
  2. Neuroscience
Download icon

Sensory transduction is required for normal development and maturation ofcochlear inner hair cell synapses

  1. John Lee
  2. Kosuke Kosuke Kawai
  3. Jeffrey R Holt  Is a corresponding author
  4. Gwenaelle Geleoc
  1. Boston Children's Hospital, United States
Research Article
  • Cited 0
  • Views 516
  • Annotations
Cite this article as: eLife 2021;10:e69433 doi: 10.7554/eLife.69433

Abstract

Acoustic overexposure and aging can damage auditory synapses in the inner ear by a process known as synaptopathy. These insults may also damage hair bundles and the sensory transduction apparatus in auditory hair cells. However, a connection between sensory transduction and synaptopathy has not been established. To evaluate potential contributions of sensory transduction to synapse formation and development, we assessed inner hair cell synapses in several genetic models of dysfunctional sensory transduction, including mice lacking Transmembrane Channel-like (Tmc) 1, Tmc2 or both, in Beethoven mice which carry a dominant Tmc1 mutation and in Spinner mice which carry a recessive mutation in Transmembrane inner ear (Tmie). Our analyses reveal loss of synapses in the absence of sensory transduction and preservation of synapses in Tmc1-null mice following restoration of sensory transduction via Tmc1 gene therapy. These results provide insight into the requirement of sensory transduction for hair cell synapse development and maturation.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Original raw data files have been uploaded to Dryad and are freely available here: https://doi.org/10.5061/dryad.fxpnvx0sb

The following data sets were generated

Article and author information

Author details

  1. John Lee

    FM Kirby Neurobiology Center, Boston Children's Hospital, Cambridge, United States
    Competing interests
    No competing interests declared.
  2. Kosuke Kosuke Kawai

    Boston Children's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  3. Jeffrey R Holt

    Boston Children's Hospital, Boston, United States
    For correspondence
    jeffrey.holt@childrens.harvard.edu
    Competing interests
    Jeffrey R Holt, J.R.H holds a patent (62/638,697) on use of AAV9-PHP.B for gene therapy in the inner ear, is a scientific founder of Audition Therapeutics and an advisor to several biotech companies focused on inner ear therapeutics. The authors declare no other conflicts of interest..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7182-8011
  4. Gwenaelle Geleoc

    Boston Children's Hospital, Boston, United States
    Competing interests
    No competing interests declared.

Funding

NIDCD (RO1 DC013521)

  • Jeffrey R Holt

NIDCD (RO1 DC008853)

  • Gwenaelle Geleoc

NIDCD (F32 DC018233)

  • John Lee

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#20-02-4149R and #00001240) at Boston Children's Hospital.

Reviewing Editor

  1. Tobias Reichenbach, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Germany

Publication history

  1. Received: April 15, 2021
  2. Accepted: November 1, 2021
  3. Accepted Manuscript published: November 4, 2021 (version 1)
  4. Version of Record published: November 17, 2021 (version 2)

Copyright

© 2021, Lee et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 516
    Page views
  • 144
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Evolutionary Biology
    2. Genetics and Genomics
    Julia M Kreiner et al.
    Research Article

    Causal mutations and their frequency in agricultural fields are well-characterized for herbicide resistance. However, we still lack understanding of their evolutionary history: the extent of parallelism in the origins of target-site resistance (TSR), how long these mutations persist, how quickly they spread, and allelic interactions that mediate their selective advantage. We addressed these questions with genomic data from 18 agricultural populations of common waterhemp (Amaranthus tuberculatus), which we show to have undergone a massive expansion over the past century, with a contemporary effective population size (Ne) estimate of 8x107. We found variation at seven characterized TSR loci, two of which had multiple amino acid substitutions, and three of which were common. These three common resistance variants show parallelism in their mutational origins, with gene flow having shaped their distribution across the landscape. Allele age estimates supported a strong role of adaptation from de novo mutations, with a median allele age of 30 suggesting that most resistance alleles arose soon after the onset of herbicide use. However, resistant lineages varied in both their age and evidence for selection over two different timescales, implying considerable heterogeneity in the forces that govern their persistence. The evolutionary history of TSR has also been shaped by both intra- and inter-locus allelic interactions. We report a signal of extended haplotype competition between two common TSR alleles, and extreme linkage with genome-wide alleles with known functions in resistance adaptation. Together, this work reveals a remarkable example of spatial parallel evolution in a metapopulation, with important implications for the management of herbicide resistance.

    1. Epidemiology and Global Health
    2. Genetics and Genomics
    Daniel W Belsky et al.
    Research Advance

    Background: Measures to quantify changes in the pace of biological aging in response to intervention are needed to evaluate geroprotective interventions for humans. Previously we showed that quantification of the pace of biological aging from a DNA-methylation blood test was possible (Belsky et al. 2020). Here we report a next-generation DNA-methylation biomarker of Pace of Aging, DunedinPACE (for Pace of Aging Calculated from the Epigenome).

    Methods: We used data from the Dunedin Study 1972-3 birth cohort tracking within-individual decline in 19 indicators of organ-system integrity across four time points spanning two decades to model Pace of Aging. We distilled this two-decade Pace of Aging into a single-time-point DNA-methylation blood-test using elastic-net regression and a DNA-methylation dataset restricted to exclude probes with low test-retest reliability. We evaluated the resulting measure, named DunedinPACE, in five additional datasets.

    Results: DunedinPACE showed high test-retest reliability, was associated with morbidity, disability, and mortality, and indicated faster aging in young adults with childhood adversity. DunedinPACE effect-sizes were similar to GrimAge Clock effect-sizes. In analysis of incident morbidity, disability, and mortality, DunedinPACE and added incremental prediction beyond GrimAge.

    Conclusions: DunedinPACE is a novel blood biomarker of the pace of aging for gerontology and geroscience.

    Funding: This research was supported by US-National Institute on Aging grants AG032282, AG061378, AG066887, and UK Medical Research Council grant MR/P005918/1.